SENP3/FIS1-regulated PFC neural mitochondrial fragmentation underlies the mechanism of electroacupuncture attenuating depressive behavior in CUMS mice

Shaoda Lai, Xiaoke Qiu, Peilin Lin, Jiandi Wu, Feifei Li, Ningjing Lai, Xin Li, Ting Tu, Jiping Zhang, Yü Huang, Zheng ZhangFrontiers in Psychiatry 2026 · DOI

TL;DR

Electroacupuncture (EA) shows promise in treating depression by reducing mitochondrial fragmentation in prefrontal cortex (PFC) neurons. This study reveals that EA achieves this by downregulating SENP3, which in turn increases SUMOylation of FIS1, ultimately mitigating neuronal damage and depressive behaviors in mice.

What Problem Does This Paper Address?

Depression is a widespread and debilitating mental disorder, and while current antidepressant treatments exist, they often suffer from slow onset of action and significant side effects. Electroacupuncture (EA) has emerged as a potential alternative therapy, but its underlying molecular mechanisms remain largely unclear. Previous research has pointed to prefrontal cortex (PFC) atrophy and neuronal damage as key pathological features of depression. Mitochondria, crucial for cellular energy and function, are implicated through a process called mitochondrial fragmentation, where they break down into smaller, dysfunctional units. This fragmentation is linked to neuronal damage and has been observed in depression. Furthermore, the SUMOylation pathway, a post-translational modification, plays a role in regulating mitochondrial dynamics and has been implicated in depression. Specifically, the enzyme SENP3 is known to deSUMOylate FIS1, a protein involved in mitochondrial fission, thereby promoting fragmentation. This paper investigates whether EA's antidepressant effects are mediated by its ability to modulate this SENP3/FIS1-regulated mitochondrial fragmentation in the PFC.

Methods

The researchers employed a multi-pronged approach to investigate the effects of EA on a mouse model of depression.

  • Animal Model: A chronic unpredictable mild stress (CUMS) model was used to induce depressive-like behaviors in mice.
  • Behavioral Tests: Standard tests like the Sucrose Preference Test (SPT) to assess anhedonia (loss of pleasure) and the Tail Suspension Test (TST) to measure behavioral despair were conducted to evaluate depressive symptoms.
  • Histology: Nissl staining was used to assess general neuronal health and structural integrity in the PFC.
  • Electron Microscopy (TEM): This technique allowed for high-resolution visualization of mitochondrial ultrastructure, enabling the quantification of fragmentation, size, and diameter.
  • Western Blotting: This method was used to measure the protein levels of key players in mitochondrial dynamics (DRP1, MFF, FIS1) and the SUMOylation pathway (SUMO2/3, SENP3).
  • Immunofluorescence: This technique was used to visualize the co-localization of FIS1 and SENP3 within PFC neurons, providing insights into their interaction.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • EA as a Neuroprotective Agent: The study strongly suggests that EA doesn't just alleviate behavioral symptoms of depression but also actively protects PFC neurons from damage.
  • Mitochondrial Fragmentation as a Key Target: The findings highlight mitochondrial fragmentation as a critical pathological process in depression that EA can effectively reverse.
  • The SENP3/FIS1 Axis is Crucial: The research pinpoints the SENP3/FIS1 pathway as a central mediator of EA's effects, moving beyond general mitochondrial dynamics to a specific regulatory mechanism.
  • SUMOylation as a Protective Mechanism: The study demonstrates that EA enhances SUMOylation, a modification that appears to counteract the detrimental effects of FIS1-mediated fragmentation.
  • SENP3 Downregulation is the Key: The most significant finding is that EA specifically reduces SENP3 levels, which is the upstream regulator that promotes FIS1-mediated fragmentation.

Key Results

  • EA treatment significantly reduced depressive-like behaviors in CUMS mice, as evidenced by increased sucrose preference and decreased immobility time in behavioral tests.
  • Nissl staining revealed amelioration of neuronal lesions in the PFC of EA-treated mice.
  • TEM imaging showed that EA reversed mitochondrial fragmentation in PFC neurons, restoring normal mitochondrial morphology, diameter, and size.
  • While DRP1 and MFF protein levels remained unchanged, EA significantly increased FIS1 expression in the PFC. This initially seems counterintuitive to reducing fragmentation, but the paper clarifies this is mediated by SUMOylation.
  • EA treatment led to a significant increase in overall SUMO levels in the PFC.
  • Crucially, EA significantly reduced SENP3 protein levels and its co-localization with FIS1 in PFC neurons.

Limitations and Future Work

The authors acknowledge several limitations:

  • Limited Exploration of the SENP3/FIS1 Pathway: The study suggests the importance of this pathway but calls for further research to fully elucidate the interaction between SENP3 and FIS1.
  • Confirmation with SENP3 Inhibitors: The authors propose using SENP3 inhibitors to definitively confirm the role of SENP3 in mediating EA's effects.
  • Mitophagy Investigation: The results hint at a potential role for mitophagy (the selective degradation of damaged mitochondria) in EA's mechanism, which warrants further investigation.

Future work should focus on these areas to provide a more comprehensive understanding of how EA exerts its antidepressant effects at the molecular and cellular level.

Summary updated

Abstract

These evidences suggested that the antidepressant effects of EA may involve modulation of mitochondrial fragmentation regulated by the SENP3/FIS1 pathway in prefrontal cortex neurons.
BibTeX
@inproceedings{lai2026senp,
  author = {Shaoda Lai and Xiaoke Qiu and Peilin Lin and Jiandi Wu and Feifei Li and Ningjing Lai and Xin Li and Ting Tu and Jiping Zhang and Yü Huang and Zheng Zhang},
  title = {{SENP3/FIS1-regulated PFC neural mitochondrial fragmentation underlies the mechanism of electroacupuncture attenuating depressive behavior in CUMS mice}},
  booktitle = {Frontiers in Psychiatry},
  year = {2026},
  doi = {10.3389/fpsyt.2025.1645757},
}
Figure